查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1842223

卵巢癌诊断市场规模、份额和趋势分析报告：按癌症类型、诊断、最终用途、地区和细分市场预测，2025-2033 年

Ovarian Cancer Diagnostics Market Size, Share & Trends Analysis Report By Cancer (Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor), By Diagnosis (Imaging, Blood Test, Biopsy), By End-use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

卵巢癌诊断市场摘要

预计 2024 年全球卵巢癌诊断市场价值将达到 17.4 亿美元，到 2033 年将达到 31.1 亿美元，2025 年至 2033 年的复合年增长率为 6.73%。

由于生物标记的发现、联邦政府的资助和新技术，卵巢癌诊断市场正在快速发展。

预计到 2025 年，美国新患者，死亡人数超过 12,000 人，凸显了早期发现的必要性。 PPP2R1A 突变作为卵巢透明细胞癌的预测生物标记物，AOA Dx 的多组体学人工智慧血液检测在有症状女性中实现了 90% 以上的准确率，超过了传统的生物标记。联邦政府的支持力道很大，国防部在 2025 财政年度为其卵巢癌研究计画拨款 6.5 亿美元，用于资助精准医疗、预防和生存研究。儘管取得了进展，但检测差距仍然存在，尤其是在老年和服务不足的女性中。总体而言，市场正在转向高精度、多体学和以患者为中心的诊断，提供了巨大的成长潜力。

卵巢癌诊断市场正在经历重大变革，其影响​​因素包括流行病学需求、生物标记的发现、技术创新以及临床策略的转变。根据美国 Cancer Society) 统计，2025 年美国将新增 20,890 例卵巢癌病例，其中 12,730 例死亡。儘管卵巢癌是女性第 11 大常见癌症，但它是癌症相关死亡的第五大原因，也是最致命的妇科恶性肿瘤。截至 2022 年，美国约有 243,572 名女性被诊断出患有卵巢癌 (SEER)，这表明越来越多的患者群体依赖早期精准诊断。值得注意的是，虽然卵巢癌死亡率正在缓慢下降，但其进展仍落后于其他癌症的治疗水平，这凸显了开发更完善的检测和分层工具的紧迫性。

市场正日益受到生物标誌物主导的创新的影响。 MD 安德森癌症中心于2025年7月取得一项突破性发现，该发现将PPP2R1A突变作为预测卵巢透明细胞癌（OCCC）免疫治疗患者生存期延长的生物标誌物，使中位总生存期延长至66.9个月，而未携带该突变的患者仅为9.2个月。这项突破性成果证明了免疫基因组学诊断的有效性，凸显了基因检测在患者分层中的作用，并刺激了对下一代分子诊断的需求。同时，早期临床试验正在探索OCCC和其他肿瘤类型的治疗靶点，重点关注PP2A通路，展现了诊断和治疗如何在精准肿瘤学框架下紧密结合。

与此同时，重大资助计划正在积聚势头。 2025年4月，美国国防部（DoD）累计为国会指导的医学研究计画（CDMRP）拨款6.5亿美元，其中一部分将分配给卵巢癌研究计画（OCRP）。 2025财年的OCRP将支持早期检测、预防、生存和精准医疗领域的高影响力研究，主要津贴包括研究者主导研究奖（最高105万美元）、临床试验学院早期职业研究者奖（最高140万美元）以及试点奖（最高35万美元）。这些投资彰显了联邦政府对加速诊断创新和改善临床疗效的坚定承诺。

儘管取得了进展，但检测差距仍然是一个重要的市场驱动因素。 2025年3月，卵巢癌研究联盟 (OCRA) 和科莫多健康组织 (Komodo Health) 报告称，儘管有普遍适用的指南，但仍约有一半的卵巢癌女性未接受基因检测。这种差距在65岁以上和用户公共保险的女性中最为明显，她们的检测率低于40%。解决这些差距对于改善治疗效果至关重要，因为基因检测是治疗方案的基础，尤其是对于符合PARP抑制剂治疗条件的BRCA突变患者。因此，像OCRA这样的组织正在扩展患者支援工具，例如其「寻找医生」平台（于2024年4月上线），该平台将患者与2000多名妇科肿瘤科医生联繫起来，并整合了临床试验搜寻功能，以提高诊断意识和采用率。

市场也受益于预防策略的策略性调整：根据英国一项大型临床试验的证据表明，基于症状的检测对死亡率的影响有限，OCRA 和妇科肿瘤学会 (SGO) 已开始倡导在 2023 年进行普遍基因检测和机会性切除术（在盆腔手术期间切除术输卵管）。这种转变反映出人们越来越依赖基于风险的诊断和基因诊断而不是传统的筛检，并正在推动分子和基因组检测的广泛应用。

技术突破也在重新定义早期检测。 2025年8月，AOA Dx在《癌症研究通讯》上发表了同行评审结果，显示其基于人工智慧的多组体学血液检测在有症状的女性中实现了高准确率，在训练队列中，所有分期卵巢癌的AUC为93%，早期卵巢癌的AUC为91%，而在独立的现实世界队列中，AUC892%和2%2%。该平台将脂质、神经节苷脂和蛋白质生物标记与机器学习相结合，提供了一种可扩展的非侵入性解决方案，超越了传统的生物标记。

此外，像OCRA的国际资料共享中心和首个卵巢和子宫内膜癌登记处（2023年）这样的倡议正在建构大规模真实世界证据生成的基础设施。透过整合患者层面的基因组和临床数据，这些努力旨在加速生物标记的发现，改善预测性诊断，并促进支付者采用，而这正是诊断行业日益重要的成长槓桿。

总体而言，卵巢癌诊断市场正迅速从传统的病理和症状识别转向基因组学主导、精准主导和以患者为中心的模式。成长的驱动力来自多种因素，包括盛行率的上升、PPP2R1A 等突破性生物标记、对公平获取基因检测的需求、数位化患者导航工具的整合、强大的联邦研究资金以及数据主导研究的国际合作。儘管检测差异、成本障碍以及缺乏有效的早期筛检工具等挑战仍然存在，但该领域正在发展成为更广泛的下一代癌症诊断市场中的一个高价值细分领域。伴随诊断、液态切片创新和免疫基因组学检测正日益决定其发展轨迹，预计未来十年将释放巨大的商业性和临床机会。

目录

第一章调查方法与范围

第二章执行摘要

第三章卵巢癌诊断市场变数、趋势和范围

  • 市场介绍/电网展望
  • 市场规模和成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 卵巢癌诊断市场分析工具
    • 波特分析
    • PESTEL分析

第四章卵巢癌诊断市场：癌症估计与趋势分析

  • 细分仪表板
  • 卵巢癌诊断市场：癌症变异分析（2024 年和 2033 年）
  • 上皮肿瘤
  • 生殖细胞肿瘤
  • 基质细胞肿瘤
  • 其他的

第五章卵巢癌诊断市场：诊断评估与趋势分析

  • 细分仪表板
  • 卵巢癌诊断市场：诊断变异分析（2024 年和 2033 年）
  • 影像
  • 血液检查
  • 切片检查
  • 其他的

第六章卵巢癌诊断市场：最终用途估计与趋势分析

  • 细分仪表板
  • 卵巢癌诊断市场：2024 年和 2033 年最终用途变化分析
  • 医院检查室
  • 癌症诊断中心
  • 研究所
  • 其他的

第七章卵巢癌诊断市场：区域估计与趋势分析

  • 2024年及2033年卵巢癌诊断市占率（按地区）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司分类
  • 公司热图分析
  • 公司简介
    • F. Hoffmann-La Roche AG
    • Johnson &Johnson Services, Inc.
    • GlaxoSmithKline Plc
    • AstraZeneca Plc
    • Siemens Healthcare GmbH
    • Abbott
    • Thermo Fisher Scientific
    • Bio-Rad Laboratories, Inc
    • Quest Diagnostics Incorporated
    • Illumina, Inc
Product Code: GVR-3-68038-421-5

Ovarian Cancer Diagnostics Market Summary

The global ovarian cancer diagnostics market size was estimated at USD 1.74 billion in 2024 and is projected to reach USD 3.11 billion by 2033, growing at a CAGR of 6.73% from 2025 to 2033. The ovarian cancer diagnostics market is advancing rapidly, driven by biomarker discovery, federal funding, and new technologies.

In 2025, the U.S. will see nearly 21,000 new cases and over 12,000 deaths, underscoring the need for earlier detection. Breakthroughs include PPP2R1A mutations as predictive biomarkers in ovarian clear cell carcinoma and AOA Dx's multi-omic, AI-powered blood test, which achieved >90% accuracy in symptomatic women, outperforming traditional biomarkers. Federal support is strong, with the DoD allocating $650M in FY25 to the Ovarian Cancer Research Program, funding precision medicine, prevention, and survivorship studies. Despite progress, testing disparities persist, particularly in older and underserved women. Overall, the market is shifting toward precision, multi-omic, and patient-centric diagnostics with significant growth potential.

The ovarian cancer diagnostics market is significantly transforming, shaped by epidemiological need, biomarker discovery, technological innovation, and shifting clinical strategies. In 2025, an estimated 20,890 new cases of ovarian cancer will be diagnosed in the U.S., with 12,730 deaths (American Cancer Society). Despite being the 11th most common cancer among women, ovarian cancer remains the fifth leading cause of cancer-related death and the deadliest gynecologic malignancy. As of 2022, approximately 243,572 women in the U.S. were living with a prior ovarian cancer diagnosis (SEER), reflecting the growing patient base that depends on early and accurate diagnostics. Significantly, mortality rates are modestly declining but lag behind improvements seen in other cancers, highlighting the urgency for better detection and stratification tools.

The market is increasingly shaped by biomarker-driven innovation. A landmark discovery in July 2025 at MD Anderson Cancer Center identified PPP2R1A mutations as a predictive biomarker for improved survival in ovarian clear cell carcinoma (OCCC) treated with immunotherapy, with median overall survival extending to 66.9 months versus 9.2 months in non-mutant patients. This breakthrough validates immunogenomic diagnostics and highlights the role of genetic testing in patient stratification, fueling demand for next-generation molecular diagnostics. Parallel efforts focus on the PP2A pathway, with early-phase trials exploring therapeutic targeting in OCCC and other tumor types, demonstrating how diagnostics and therapeutics converge in a precision oncology framework.

In parallel, large-scale funding initiatives are reinforcing this momentum. In April 2025, the U.S. Department of Defense (DoD) announced $650 million in appropriations for its Congressionally Directed Medical Research Programs (CDMRP), with a dedicated portion for the Ovarian Cancer Research Program (OCRP). The FY25 OCRP will support high-impact research on early detection, prevention, survivorship, and precision medicine, offering major grants such as the Investigator-Initiated Research Award (up to $1.05M), the Clinical Trial Academy - Early Career Investigator Award (up to $1.4M), and Pilot Awards (up to $350K). These investments signal strong federal backing to accelerate diagnostic innovation and improve clinical outcomes.

Despite advances, testing gaps remain a significant market driver. In March 2025, the Ovarian Cancer Research Alliance (OCRA) and Komodo Health reported that nearly half of women with ovarian cancer are not receiving genetic testing, despite universal guidelines. Disparities are most evident among women over 65 and those on public insurance, where testing rates fall below 40%. Since genetic testing underpins therapy selection particularly for BRCA mutation-positive patients eligible for PARP inhibitors addressing these gaps is central to improving outcomes. As a result, organizations like OCRA are expanding patient-support tools, such as the "Find a Doctor" platform (launched April 2024), which connects patients to more than 2,000 gynecologic oncology specialists and integrates trial-finder functionality, increasing awareness and adoption of diagnostics.

The market also benefits from strategic realignment in preventive strategies. Following evidence from large-scale UK trials showing the limited impact of symptom-based detection on mortality, OCRA and the Society of Gynecologic Oncology (SGO) began advocating for universal genetic testing and opportunistic salpingectomy (fallopian tube removal during pelvic surgery) in 2023. This shift reflects a growing reliance on risk-based and genetic diagnostics rather than conventional screening, driving greater uptake of molecular and genomic tests.

Technological breakthroughs are also redefining early detection. In August 2025, AOA Dx published peer-reviewed results in Cancer Research Communications showing that its multi-omic, AI-powered blood test achieved strong accuracy in symptomatic women, with an AUC of 93% for all stages and 91% for early-stage ovarian cancer in training cohorts, and 92% and 88% respectively, in independent real-world cohorts. The platform outperformed traditional biomarkers by combining lipid, ganglioside, and protein biomarkers with machine learning, offering a scalable, non-invasive solution that could transform early-stage detection, where survival benefits are most significant.

Furthermore, initiatives such as OCRA's international data commons and the first ovarian ad endometrial cancer registry (2023) create the infrastructure for large-scale real-world evidence generation. By consolidating patient-level genomic and clinical data, these efforts aim to accelerate biomarker discovery, improve predictive diagnostics, and inform payor adoption an increasingly important growth lever for the diagnostics industry.

Overall, the ovarian cancer diagnostics market moves rapidly from traditional pathology and symptom awareness toward a genomics-led, precision-driven, patient-centered model. Growth is fueled by a convergence of factors: rising disease prevalence, breakthrough biomarkers such as PPP2R1A, demand for equitable access to genetic testing, integration of digital patient navigation tools, robust federal research funding, and international collaboration in data-driven research. While challenges around testing disparities, cost barriers, and lack of validated early screening tools persist, the sector is evolving into a high-value segment of the broader next-generation cancer diagnostics market. Its trajectory is increasingly defined by companion diagnostics, liquid biopsy innovations, and immunogenomic testing, which are expected to unlock significant commercial and clinical opportunities over the next decade.

Global Ovarian Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global ovarian cancer diagnostics market report based on cancer, diagnosis, end-use, and region:

  • Cancer Outlook (Revenue, USD Million, 2021 - 2033)
  • Epithelial Tumor
  • Germ Cell Tumor
  • Stromal Cell Tumor
  • Others
  • Diagnosis Outlook (Revenue, USD Million, 2021 - 2033)
  • Imaging
    • Ultrasound
    • CT Scan
    • MRI Scan
    • PET Scan
    • Others
  • Blood Test
    • CA125
    • HER2
    • BRCA
    • CEA
    • ER & PR
    • KRAS Mutation
    • Others
  • Biopsy
  • Others
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Laboratories
  • Cancer Diagnostic Centers
  • Research Institutes
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • UAE
    • South Arabia
    • South Africa
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Ovarian Cancer Diagnostics Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Ovarian Cancer Diagnostics Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Ovarian Cancer Diagnostics Market: Cancer Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Ovarian Cancer Diagnostics Market: Cancer Movement Analysis, 2024 & 2033 (USD Million)
  • 4.3. Epithelial Tumor
    • 4.3.1. Epithelial Tumor Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Germ Cell Tumor
    • 4.4.1. Germ Cell Tumor Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Stromal Cell Tumor
    • 4.5.1. Stromal Cell Tumor Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Ovarian Cancer Diagnostics Market: Diagnosis Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Ovarian Cancer Diagnostics Market: Diagnosis Movement Analysis, 2024 & 2033 (USD Million)
  • 5.3. Imaging
    • 5.3.1. Imaging Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Blood Test
    • 5.4.1. Blood Test Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Biopsy
    • 5.5.1. Biopsy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Ovarian Cancer Diagnostics Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Ovarian Cancer Diagnostics Market: End Use Movement Analysis, 2024 & 2033 (USD Million)
  • 6.3. Hospital Laboratories
    • 6.3.1. Hospital Laboratories Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Cancer Diagnostic Centers
    • 6.4.1. Cancer Diagnostic Centers Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Research Institutes
    • 6.5.1. Research Institutes Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Ovarian Cancer Diagnostics Market: Regional Estimates & Trend Analysis

  • 7.1. Ovarian Cancer Diagnostics Market Share, By Region, 2024 & 2033 (USD Million)
  • 7.2. North America
    • 7.2.1. North America Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. China Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. South Africa
      • 7.6.3.1. South Africa Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. F. Hoffmann-La Roche AG
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Johnson & Johnson Services, Inc.
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. GlaxoSmithKline Plc
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. AstraZeneca Plc
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Siemens Healthcare GmbH
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Abbott
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Thermo Fisher Scientific
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Bio-Rad Laboratories, Inc
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Quest Diagnostics Incorporated
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Illumina, Inc
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Regulatory Framework
  • Table 4 Global Ovarian Cancer Diagnostics Market, By Region, 2021 - 2033 (USD Million)
  • Table 5 Global Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 6 Global Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 7 Global Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 8 North America Ovarian Cancer Diagnostics Market, By Country, 2021- 2033 (USD Million)
  • Table 9 North America Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 10 North America Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 11 North America Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 12 U.S. Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 13 U.S. Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 14 U.S. Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 15 Canada Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 16 Canada Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 17 Canada Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 18 Mexico Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 19 Mexico Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 20 Mexico Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 21 Europe Ovarian Cancer Diagnostics Market, By Country, 2021- 2033 (USD Million)
  • Table 22 Europe Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 23 Europe Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 24 Europe Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 25 UK Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 26 UK Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 27 UK Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 28 Germany Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 29 Germany Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 30 Germany Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 31 France Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 32 France Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 33 France Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 34 Spain Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 35 Spain Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 36 Spain Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 37 Italy Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 38 Italy Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 39 Italy Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 40 Denmark Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 41 Denmark Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 42 Denmark Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 43 Sweden Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 44 Sweden Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 45 Sweden Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 46 Norway Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 47 Norway Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 48 Norway Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific Ovarian Cancer Diagnostics Market, By Country, 2021- 2033 (USD Million)
  • Table 50 Asia Pacific Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 52 Asia Pacific Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 53 Japan Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 54 Japan Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 55 Japan Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 56 China Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 57 China Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 58 China Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 59 Australia Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 60 Australia Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 61 Australia Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 62 Thailand Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 63 Thailand Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 64 Thailand Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 65 India Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 66 India Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 67 India Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 68 South Korea Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 69 South Korea Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 70 South Korea Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 71 Latin America Ovarian Cancer Diagnostics Market, By Country, 2021- 2033 (USD Million)
  • Table 72 Latin America Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 73 Latin America Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 74 Latin America Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 75 Brazil Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 76 Brazil Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 77 Brazil Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 78 Argentina Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 79 Argentina Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 80 Argentina Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 81 MEA Ovarian Cancer Diagnostics Market, By Country, 2021- 2033 (USD Million)
  • Table 82 MEA Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 83 MEA Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 84 MEA Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 85 South Africa Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 86 South Africa Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 87 South Africa Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 90 Saudi Arabia Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 91 UAE Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 92 UAE Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 93 UAE Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 94 Kuwait Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 95 Kuwait Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 96 Kuwait Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Ovarian cancer diagnostics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Ovarian cancer diagnostics market snapshot
  • Fig. 10 Penetration and growth prospect mapping for application, 2022 (USD Million)
  • Fig. 11 Market Dynamics
  • Fig. 12 Ovarian cancer diagnostics market driver impact
  • Fig. 13 Ovarian cancer diagnostics market restraint impact
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 Ovarian cancer diagnostics market: Diagnosis outlook and key takeaways
  • Fig. 16 Imaging market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 17 Blood test market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 18 Biopsy market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 19 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 20 Ovarian cancer diagnostics market : Cancer outlook and key takeaways
  • Fig. 21 Ovarian cancer diagnostics market: Cancer movement analysis
  • Fig. 22 Epithelial tumor market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 23 Germ cell tumor market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 24 Stromal cell tumor market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 25 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 26 Ovarian cancer diagnostics market : End Use outlook and key takeaways
  • Fig. 27 Ovarian cancer diagnostics market: End Use movement analysis
  • Fig. 28 Hospital laboratories market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 29 Cancer diagnostic centers market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 30 Research institutes market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 31 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 32 Ovarian Cancer Diagnostics Market: Regional outlook and key takeaways
  • Fig. 33 Ovarian Cancer Diagnostics Market: Regional movement analysis
  • Fig. 34 North America
  • Fig. 35 North America market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 36 U.S.
  • Fig. 37 U.S. market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 38 Canada
  • Fig. 39 Canada market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 40 Mexico
  • Fig. 41 Mexico market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 42 Europe
  • Fig. 43 Europe market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 44 UK
  • Fig. 45 UK market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 46 Germany
  • Fig. 47 Germany market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 48 France
  • Fig. 49 France market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 50 Spain
  • Fig. 51 Spain market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 52 Italy
  • Fig. 53 Italy market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 54 Denmark
  • Fig. 55 Denmark market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 56 Sweden
  • Fig. 57 Sweden market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 58 Norway
  • Fig. 59 Norway market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 60 Asia Pacific
  • Fig. 61 Asia Pacific market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 62 Japan
  • Fig. 63 Japan market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 64 China
  • Fig. 65 China. market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 66 India
  • Fig. 67 India market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 68 Thailad
  • Fig. 69 Thailand market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 70 Australia
  • Fig. 71 Australia market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 72 South Korea
  • Fig. 73 South Korea market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 74 Latin America
  • Fig. 75 Latin America market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 76 Brazil
  • Fig. 77 Brazil market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 78 Argentina
  • Fig. 79 Argentina market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 80 MEA
  • Fig. 81 MEA market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 82 South Africa
  • Fig. 83 South Africa market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 84 Saudi Arabia
  • Fig. 85 Saudi Arabia market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 86 UAE
  • Fig. 87 UAE market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 88 Kuwait
  • Fig. 89 Kuwait market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 90 Ansoff Matrix
  • Fig. 91 Strategy mapping
  • Fig. 92 Company market share analysis, 2022
  • Fig. 93 Heat Map Analysis
  • Fig. 94 Market differentiators
  • Fig. 95 Heat Map Analysis